NEW YORK – BiomX of Israel said on Wednesday that it is collaborating with Boehringer Ingelheim to discover biomarkers associated with patient phenotypes in inflammatory bowel disease.
Under the agreement, BiomX will generate metagenomic data for gut microbiome samples from IBD patients using its XMarker biomarker discovery platform.